Vaxcyte and Lonza sign new commercial manufacturing agreement for PCVs
Vaxcyte has signed a new commercial agreement with Lonza for the global manufacture of broad-spectrum pneumococcal conjugate vaccines (PCVs). Building on an existing collaboration, the new deal will enable the commercialisation of Vaxcyte’s PCV candidates, VAX-24 and VAX-31, for both paediatric and adult populations globally. This agreement supports Vaxcyte's strategy to leverage Lonza's existing infrastructure for clinical development and the upcoming US launch of VAX-24 for adults. Lonza will offer Vaxcyte a custom-built manufacturing suite as part of its Ibex Dedicate Biopark at its site in Visp, Switzerland. The suite will be used to produce essential components for Vaxcyte's PCV franchise. Starting with VAX-24, which is advancing towards late-stage clinical trials, Vaxcyte's manufacturing facility will help address the long-term global market needs for both adults and children. The manufacturing suite's design is almost finished and equipment installation is set to commence in 2024. Lonza will create 300 new jobs at peak production. Lonza biologics president Jean-Christophe Hyvert stated: “Having supported the early-stage clinical development of Vaxcyte’s PCV programmes, we are pleased to continue our long-standing collaboration by supporting the late-stage clinical manufacturing utilising our unique IbexDedicate offering, with the capability to provide commercial supply of their products.” In 2022 to 2023, Vaxcyte achieved significant advancements in its VAX-24 clinical programme, including two positive Phase II results in adults and the commencement of a Phase II study in infants. Vaxcyte CEO and co-founder Grant Pickering stated: “Following the successful completion of our VAX-24 Phase II adult studies, and as we prepare for Phase III clinical studies, we are excited to expand our relationship with Lonza, a pre-eminent contract development and manufacturing organisation, and put into motion the key steps required to establish large-scale and long-term commercial manufacturing capacity for our PCV candidates.”
Vaxcyte has signed a new commercial agreement with Lonza for the global manufacture of broad-spectrum PCVs.
What's Your Reaction?
